Calcium acetate/magnesium carbonate

Calcium acetate/magnesium carbonate

Combination of
Calcium acetate	Mineral supplement
Magnesium carbonate	Mineral supplement
Clinical data
Pregnancy cat.	n/a
Legal status	Rx Prescription only
Routes	Oral
Identifiers
CAS number	62-54-4 546-93-0
ATC code	V03AE04
PubChem	CID 11029
Y(what is this?)  acetate/magnesium carbonate (verify)

Calcium acetate/magnesium carbonate is a fixed-dose combination drug that contains 110 mg calcium and 60 mg magnesium indicated as a phosphate binder for dialysis patients suffering from hyperphosphataemia (abnormal high serum phosphorus levels).^[1] It is registered by Fresenius Medical Care under the trade names Renepho (Belgium) and OsvaRen (other EMEA).

Clinical use

Phosphorus is contained in food with high protein content as well as in processed food. It is absorbed by the gut. Healthy kidneys remove excess phosphorus from the body. One of the consequences of renal failure is inadequate removal of phosphorus resulting in increased serum phosphorus levels. This may worsen the overproduction of parathyroid hormone (hyperparathyroidism), may lead to calcification of blood vessels and is associated with cardiovascular mortality.^[2] In addition to dialysis therapy and dietary restrictions, a pharmaceutical therapy to lower serum phosphorus levels is recommended.^[3]

Mechanism of action

Calcium acetate/magnesium carbonate is taken orally together with the meal.^[1] Calcium acetate and magnesium carbonate compounds bind phosphorus derived from food thereby forming indigestible phosphate salts in the intestine that are subsequently excreted with the faeces. The aim of the therapy is to reach a normal serum phosphorus level, i.e. between 0.81 - 1.45 mmol/l (2.5 - 4.5 mg/dl).^[2]

Side effects

Side effects from pharmaceutical therapy such as gastrointestinal disorders, e.g. nausea, constipation or diarrhoea may occur, as well as metabolism and nutritional disorders, e.g. hypercalcaemia or hypermagnesaemia.^[1]

See also

• List of prescription drugs by countries
• Magnesium carbonate
• Phosphate binders
• Prescription drug
• Hyperphosphataemia
• Chronic kidney disease

References

1. ^ ^{a b c} Osvaren – Summary of Product Characteristics; Retrieved on 17 January 2010.
2. ^ ^{a b} National Kidney Foundation, Kidney Disease Improving Global Outcomes (KDIGO). Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney International, Aug. 2009; 42: pp. 1–130.
3. ^ “What are medications for phosphorus control?”, National Kidney Foundation, URL: http://www.kidney.org/atoz/content/phosphorus.cfm ; Retrieved on 17 January 2010

External links

• Phosphorus and Your CKD Diet - kidney.org
• Information on Hyperphosphataemia by Fresenius Medical Care - fmc-renalpharma.com